title: [Dutasteride in the treatment of benign prostatic hyperplasia: an update].
abstract: Benign prostatic hyperplasia (BPH) is a common disease in older men. At present, 5alpha reductase inhibitor-based medication, preferred by most BPH patients as the first-choice therapy, is taking place of traditional transurethral resection of the prostate. This article presents an update of the researches on the treatment of BPH with dutasteride--a novel 5 alpha-reductase inhibitor.
authors.affiliation: Department of Urology, The First Renmin Hospital of Lanzhou, Lanzhou, Gansu 730050, China.
authors.forename: Hong-jie
authors.initials: HJ
authors.lastname: Chen
authors.forename: Yi-rong
authors.initials: YR
authors.lastname: Chen
mesh_terms: D058891:5-alpha Reductase Inhibitors / Q000627:therapeutic use*; D001378:Azasteroids / Q000627:therapeutic use*; D000068538:Dutasteride; D006801:Humans; D008297:Male; D011470:Prostatic Hyperplasia / Q000188:drug therapy*
chemical_list: D058891:5-alpha Reductase Inhibitors; D001378:Azasteroids; D000068538:Dutasteride